Raynaud's Phenomenon Secondary to Systemic Sclerosis
5 clinical trials · Condition
◉ Watch Raynaud's Phenomenon Secondary to Systemic Sclerosis
| Record | Firm | Date |
|---|---|---|
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (NCT04915950) | Pfizer | 2021-11-03 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (NCT04040322) | Civi Biopharma, Inc. | 2019-10-14 |
| Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (NCT02228850) | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 2014-11-01 |
Track Raynaud's Phenomenon Secondary to Systemic Sclerosis automatically
Every clearance here is in the API, with alerts when new ones post.